Sabina Lee

Recent advances in artificial intelligence (AI) has played a pivotal role in optimizing the small-molecule synthesis, standardization, scalability and CRO-based validation. Despite a dose of skepticism about the growing hype around AI, introducing greater automation to a drug design hypothesis has enabled more effectual searches for various compound characteristics concerning efficacy, pharmacokinetics and safety.

What is "supercomputing"? It refers to processing a massive quantity of complex data-intensive and computation-heavy problems often found in scientific or engineering projects. Using a powerful class of ‘multiple’ computer systems working in parallel, supercomputing is built into an infrastructure that is supporting a vast array of disciplines. From quantum mechanics and molecular modeling to weather forecasting and exploration of oil and gas, it has brought about massive waves of transformations to some of the key industries today.

STB CLOUD is Syntekabio’s latest cloud-based, fully automated AI platform. It’s designed for developers to engage in their drug discovery and development processes to find drug candidates easier and faster.

Artificial intelligence (A.I.) and big data in a synergistic integration have led to promising results in new drug development by drastically reducing cost and time. This trend in the biopharmaceutical market has emerged as a new industry standard as startups—each with distinctive core A.I. algorithm—fiercely compete to capture their global market share. Syntekabio, the first KOSDAQ-listed A.I. driven biotech company in South Korea, shares its view on the current and future trajectory of A.I. drug discovery and development in a series of exclusive articles for BiopharmaTrend.

Before the age of modern drug discovery, the pharmaceutical industry had been plagued with uncertainty and processing challenges, including the timescales, length, complexity and cost of drug discovery. So, what is transforming the biopharma industry and the future of our humanity? The answer lies in two words: artificial intelligence (AI).

Once an obscure concept when the term was coined in 1956, AI has become ubiquitous in 2023. It’s been widely adopted to perceive, synthesize and infer information, retool processes, and restructure products. From Alexa to facial recognition, AI and machine learning are part of everyday life from here to Timbuktu. It is also central to driving three major factors most critical for companies: the ability to cut expenses, develop faster, and grow efficiently in less time.